Working… Menu

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02927964
Recruitment Status : Recruiting
First Posted : October 7, 2016
Last Update Posted : July 7, 2020
Janssen, LP
National Institutes of Health (NIH)
The Leukemia and Lymphoma Society
Rising Tide Foundation
Information provided by (Responsible Party):
Robert Lowsky, Stanford University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2021